This page shows the latest T-DM1 news and features for those working in and with pharma, biotech and healthcare.
emtansine (T-DM1). ... In the trial, nearly all patients treated with Enhertu were alive at one year (94.1%) compared to 85.9% of patients treated with T-DM1.
The results of the phase 3 trial showed that Enhertu reduced the risk of disease progression or death by 72% vs trastuzumab emtansine (T-DM1). ... Nearly all patients treated with Enhertu were alive at one year (94.1%) compared to 85.9% of patients
Those dendritic cells can activate cytotoxic T-cells which, after replicating, track and eradicate cancer cells. ... Kadcyla (trastuzumab emtansine, Genentech of Roche) targets HER2 receptors present in breast cancer and delivers an anti-microtubule
Expectations are high for the Kadcyla, which is an antibody-drug conjugate (ADC) that combines the monoclonal antibody in Herceptin with ImmunoGen's DM1, a cytotoxic payload designed to boost its
FDA approval for Kadcyla (formerly T-DM1) in breast cancer. Roche won approval in the US late last week for Kadcyla, its much-anticipated follow-up to breast cancer blockbuster Herceptin. ... The FDA has given the go-ahead to Kadcyla, formerly known as
pylori", according to the partners. Chugai Pharmaceutical has filed for approval of trastuzumab emtansine (T-DM1) - originally developed by Roche/Genentech as a follow-up to their Herceptin (trastuzumab) blockbuster - for ... Chugai has commercialisation
More from news
Approximately 2 fully matching, plus 8 partially matching documents found.
It was noteworthy that the Celltrion's announcement happened to coincide with Roche's clinical data presentation of its Herceptin biobetter, Trastuzumab-emtansine (T-DM1).
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
investigational medicines, such as breast cancer drug T-DM1.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by...